Physician

Naixi Nick Chen, M.D., PH.D.

According to 2025 Medicare claims, Naixi Chen, M.D., PH.D. (NPI: 1265490312) practices hematology/oncology in the Seattle-Bellevue-Kent, WA market, with the plurality of this provider's patient population coming from King, WA. This provider's primary affiliated billing organization is SOUTH SOUND ONCOLOGY SERVICES, P.C. (NPI: 1376938506; TIN: 262231158) and primary practice location at 98057-4803.

Chen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 141 traditional Medicare patients, billed 376,487 HCPCS/CPT codes, and received $4,406,498 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 739 prescription claims across 102 beneficiaries totaling $1,971,368 in drug costs, led by Erleada (Apalutamide). DME data shows 110 claims. Open Payments data shows 239 records totaling $6,481. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,761,212 to $4,406,498. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $325,522 to $1,971,368. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	105	132,557	$1,761,212
2016	110	400,763	$2,471,778
2017	115	345,731	$2,876,338
2018	142	460,688	$3,864,021
2019	140	513,564	$3,905,633
2020	162	503,530	$3,734,344
2021	152	417,725	$3,670,788
2022	130	330,562	$4,164,342
2023	146	420,716	$3,864,512
2024	141	376,487	$4,406,498

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	50	487	$325,522
2016	82	885	$715,868
2017	76	933	$645,948
2018	95	916	$1,223,374
2019	103	911	$1,376,472
2020	104	730	$1,136,392
2021	108	898	$1,612,482
2022	100	579	$1,532,419
2023	107	826	$1,719,993
2024	102	739	$1,971,368

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	25	77	$18,930
2016	14	96	$17,220
2017	34	135	$28,817
2018	11	102	$9,550
2019	11	96	$8,488
2020	12	68	$4,801
2021	N/R	127	$17,285
2022	N/R	59	$1,573
2023	N/R	11	$393
2024	N/R	110	$5,195

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	118	650	$105
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	86	998	$7
36415	Insertion of needle into vein for collection of blood sample	75	327	$6
J3475	Injection, magnesium sulfate, per 500 mg	70	2,904	$0
J3490	Unclassified drugs	73	77,874	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Erleada	Apalutamide	25	810	$372,545
Verzenio	Abemaciclib	14	392	$250,371
Abiraterone Acetate	Abiraterone Acetate	11	330	$87,546
Zarxio	Filgrastim-Sndz	45	374	$71,270
Nivestym	Filgrastim-Aafi	12	144	$23,686

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0781	Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient	Y	N/R	15	$2,697
J8530	Cyclophosphamide; oral, 25 mg	N	N/R	33	$1,276
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	31	$583
J8521	Capecitabine, oral, 500 mg	N	N/R	14	$424
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	17	$213

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	239	$6,481	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Naixi Nick Chen, M.D., PH.D.?

Tedicare shows public-source Medicare data for Naixi Nick Chen, M.D., PH.D. (NPI 1265490312), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Naixi Nick Chen, M.D., PH.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Naixi Nick Chen, M.D., PH.D.?

Naixi Nick Chen, M.D., PH.D. is linked to SOUTH SOUND ONCOLOGY SERVICES, P.C. (billing NPI 1376938506) in the available physician profile data.

Does Naixi Nick Chen, M.D., PH.D. have Open Payments data?

Naixi Nick Chen, M.D., PH.D. has 239 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.